Literature DB >> 19322980

Exenatide and acute pancreatitis.

N R Tripathy1, S Basha, R Jain, S Shetty, A Ramachandran.   

Abstract

For a female, type 2 diabetic patient, with 4 years duration of diabetes, Exenatide (Byetta) was prescribed as glycaemic control was not satisfactory along with Glimepiride and Metformin. She had gastrointestinal disturbances, since the first day of the injection. From the eighth day she developed signs of acute pancreatitis which was confirmed with CT-Scan and biochemical investigations. Byetta was withdrawn, the patient was treated for acute pancreatitis and the symptoms subsided.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19322980

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  19 in total

1.  Collateral damage: the conundrum of drug safety.

Authors:  E A M Gale
Journal:  Diabetologia       Date:  2009-10       Impact factor: 10.122

Review 2.  Adverse Effects of GLP-1 Receptor Agonists.

Authors:  Theodosios D Filippatos; Thalia V Panagiotopoulou; Moses S Elisaf
Journal:  Rev Diabet Stud       Date:  2015-02-10

3.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Authors:  Michael Elashoff; Aleksey V Matveyenko; Belinda Gier; Robert Elashoff; Peter C Butler
Journal:  Gastroenterology       Date:  2011-02-18       Impact factor: 22.682

4.  Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

Authors:  Rajesh Garg; William Chen; Merri Pendergrass
Journal:  Diabetes Care       Date:  2010-08-03       Impact factor: 17.152

Review 5.  Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.

Authors:  Hui Peng; Laura L Want; Vanita R Aroda
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

6.  No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.

Authors:  K Tatarkiewicz; P Belanger; G Gu; D Parkes; D Roy
Journal:  Diabetes Obes Metab       Date:  2012-12-07       Impact factor: 6.577

7.  Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Authors:  P C Butler; A V Matveyenko; S Dry; A Bhushan; R Elashoff
Journal:  Diabetologia       Date:  2009-11-06       Impact factor: 10.122

8.  GLP-1-based therapy for diabetes: what you do not know can hurt you.

Authors:  Peter C Butler; Sarah Dry; Robert Elashoff
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

9.  Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER.

Authors:  Véronique Gigoux; Daniel Fourmy
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-29       Impact factor: 5.555

10.  Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.

Authors:  Christoph Rosak; Gabriele Mertes
Journal:  Diabetes Metab Syndr Obes       Date:  2012-10-12       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.